Moleculin Biotech
MBRX
20 hedge funds and large institutions have $1.58M invested in Moleculin Biotech in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
23% less capital invested
Capital invested by funds: $2.05M → $1.58M (-$479K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$91.9K |
| 2 |
Renaissance Technologies
New York
|
+$51.7K |
| 3 |
Bank of New York Mellon
New York
|
+$43.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$31.6K |
| 5 |
WIC
Whitegate Investment Counselors
Concord,
New Hampshire
|
+$31.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$14.4K |
| 2 |
LNWWM
Laird Norton Wetherby Wealth Management
San Francisco,
California
|
-$14.4K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$13K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.74K |
| 5 |
AWM
Avondale Wealth Management
West Lake Hills,
Texas
|
-$4K |
MBRX Hedge Fund Activity: Q4 2018 in Review
20 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2018, worth a combined $1.58M — down 23% from $2.05M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MBRX positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 2 trimmed.
The largest buyer was CIBC World Market, adding an estimated $91.9K. The largest seller was Commonwealth Equity Services, cutting an estimated $14.4K.
- 20 institutional investors held Moleculin Biotech (MBRX) as of Q4 2018, up from 19 in Q3 2018.
- Funds reported $1.58M of Moleculin Biotech stock for Q4 2018, down 23% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q4 2018 and 4 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q4 2018 was CIBC World Market, an estimated $91.9K added.
- The largest Moleculin Biotech seller in Q4 2018 was Commonwealth Equity Services, an estimated $14.4K sold.
Based on aggregated 13F filings for Q4 2018.